Pacira BioSciences Presents Real-World Evidence of EXPAREL and ioveraº for Knee Pain Management
ByAinvest
Monday, Mar 2, 2026 8:03 am ET1min read
PCRX--
Pacira BioSciences presented real-world studies from its Innovations in Genicular Outcomes Registry (IGOR) at the American Academy of Orthopedic Surgeons 2026 Annual Meeting. The studies highlighted the clinical effectiveness of EXPAREL for total knee arthroplasty and long-term pain management with iovera for patients with osteoarthritis of the knee. Data demonstrated improvements in pain, opioid use, function, and length of stay with EXPAREL after TKA and longer-term improvement in pain and function for up to 12 months with iovera.

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue



Comments
No comments yet